ROIV (Roivant Sciences) Ending Cash Position: $1,430.98 Mil (As of Mar. 2026)


ROIV Roivant Sciences Ltd ROIV
51 GF Score
Price $35.98
GF Value $10.95
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Ending Cash Position?

Roivant Sciences ROIV -2.34% 51 Ending Cash Position is $1,430.98 Mil as of Mar. 2026. GuruFocus rates ROIV with a GF Score™ of 51/100 and a GF Value™ of $10.95 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Roivant Sciences's Ending Cash Position for the quarter that ended in Mar. 2026 was $1,430.98 Mil.

Roivant Sciences's quarterly Ending Cash Position increased from Sep. 2025 ($1,247.16 Mil) to Dec. 2025 ($1,488.77 Mil) but then declined from Dec. 2025 ($1,488.77 Mil) to Mar. 2026 ($1,430.98 Mil).

Roivant Sciences's annual Ending Cash Position declined from Mar. 2024 ($6,550.45 Mil) to Mar. 2025 ($2,725.66 Mil) and declined from Mar. 2025 ($2,725.66 Mil) to Mar. 2026 ($1,430.98 Mil).

Roivant Sciences Ending Cash Position Related Terms

Roivant Sciences Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Roivant Sciences's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Roivant Sciences Ending Cash Position Chart

Roivant Sciences Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Ending Cash Position
Get a 7-Day Free Trial 2,074.03 1,692.12 6,550.45 2,725.66 1,430.98

Roivant Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,725.66 1,248.61 1,247.16 1,488.77 1,430.98
ROIV
51GF Score
Roivant Sciences Ltd ROIV
Ending Cash Position is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Roivant Sciences Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Roivant Sciences's Ending Cash Position for the fiscal year that ended in Mar. 2026 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=2725.661+-1294.679
=1,430.98

Roivant Sciences's Ending Cash Position for the quarter that ended in Mar. 2026 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=1488.77+-57.788
=1,430.98

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of $1,430.98 Mil mean?
Roivant Sciences (ROIV) has a Ending Cash Position of $1,430.98 Mil as of Mar. 2026. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Roivant Sciences and its competitors.
Is Roivant Sciences' Ending Cash Position too high?
Roivant Sciences' current Ending Cash Position is $1,430.98 Mil. Overall, Roivant Sciences has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Roivant Sciences' Ending Cash Position compare to RPRX and BNTX?
Roivant Sciences' Ending Cash Position of $1,430.98 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Roivant Sciences and its competitors. Roivant Sciences's current Ending Cash Position is $1,430.98 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Roivant Sciences stock overvalued right now?
Based on GuruFocus' analysis, Roivant Sciences (ROIV) is currently considered Significantly Overvalued. The stock's GF Value™ is $10.95, compared to a current price of $35.98 — trading 228.6% above its estimated fair value. The current Ending Cash Position is $1,430.98 Mil. Roivant Sciences' overall GF Score™ is 51/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Roivant Sciences (ROIV), the current Ending Cash Position is $1,430.98 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Roivant Sciences (ROIV) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of $35.98 is trading 228.6% above its estimated GF Value™ of $10.95. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for ROIV:

  • Ending Cash Position: $1,430.98 Mil
  • GF Value™: $10.95 vs. price of $35.98 (228.6% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the ROIV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges 87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score

Get the complete analysis for ROIV

Ending Cash Position is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$35.98
Price
$10.95
GF Value